Brentuximab-vedotin maintenance following chemotherapy without irradiation for primary intracranial embryonal carcinoma in down syndrome.

Abu Arja, Mohammad H

Brentuximab-vedotin maintenance following chemotherapy without irradiation for primary intracranial embryonal carcinoma in down syndrome. [electronic resource] - Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery 04 2018 - 777-780 p. digital

Publication Type: Case Reports; Journal Article

1433-0350

10.1007/s00381-017-3690-9 doi


Adolescent
Antineoplastic Agents--therapeutic use
Brentuximab Vedotin
Carcinoma, Embryonal--complications
Central Nervous System Neoplasms--drug therapy
Down Syndrome--complications
Female
Humans
Immunoconjugates
Ki-1 Antigen--metabolism
Ki-67 Antigen--metabolism
Magnetic Resonance Imaging
Octamer Transcription Factor-3--metabolism
Retrospective Studies